Thoracic Cancer Clinical Trials
At Orlando Health Cancer Institute, our thoracic cancer experts participate in a range of cancer research and clinical trials. Our research helps discover new, effective treatments for thoracic cancer as well as new ways to improve the quality of life for those with cancer.
If your current treatments are not effective, clinical trials can offer you more treatment options. Your clinical trial treatment options may include new chemotherapy medicines, radiation therapy techniques or other types of treatments. Your medical team will discuss with you any options you may have for treatments through clinical trials.
-
A Phase 2B, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based hemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS +
A Phase 2B, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based hemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS
Protocol No: 61186372NSC2012
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667076
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 8016
File Name: Subject Eligibility _Screening Checklist_61186372NSC2012.docx
URL:
Objective
To study how well amivantamab works when given with lazertinib or chemotherapy in patients with a certain type of non-small cell lung cancer that has an EGFR mutation.
-
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer +
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No: 90301900NSC2001
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667908
Phase: II
Principal Investigators: Tirrell Johnson, MD
Objective
To determine whether JNJ-90301900 as a radioenhancer added to cCRT followed by cIT can improve objective response rate in participants with locally advanced and unresectable Stage IIIA and IIIB NSCLC
-
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer +
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer
Protocol No: EIK1001-005
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06246110
Phase: II
Principal Investigators: Jennifer Tseng, MD
Eligibility Document -
Attachment Id: 7850
File Name: Subject Eligibility _Screening Checklist Version_EIK1001-005_V1_28Oct2024.docx
URL:
Objective
This study is testing a new drug, EIK1001, with pembrolizumab and chemotherapy in people with stage 4 non-small cell lung cancer to evaluate safety during treatment.
-
A Prospective, Open-label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) +
A Prospective, Open-label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Protocol No: GCT1046-06
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06635824
Phase: III
Principal Investigators: Jennifer Tseng, MD
Eligibility Document -
Attachment Id: 12414
File Name: GCT1046-06_Subject Eligibility _Screening Checklist_PA1_v2.0_REVISION_FINAL.02Jun2025.docx
URL:
Objective
The purpose of this study is to see if the drug acasunlimab (GEN1046) combined with pembrolizumab works better than docetaxel for people with PD-L1 positive metastatic non-small cell lung cancer whose cancer has progressed after treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. The amin goal is to find out whether the study treatment helps patients live longer.
-
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors +
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
Protocol No: IDE397-001
Age Group: Adult
Disease Sites: Esophagus, Lung, Melanoma, Skin, Pancreas
NCT Id: NCT04794699
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 7934
File Name: Subject Eligibility Checklist Version 15MAR2024 final.docx
URL:
Objective
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE397 alone and in combination with docetaxel or paclitaxel in adult participants with advanced solid tumors.
-
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer +
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Protocol No: IOV-GM1-201
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05361174
Phase: II/III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 11553
File Name: Subject Eligibility _Baseline Checklist GM1.docx
URL:
Objective
This study is testing a new type of immune cell therapy called IOV-4001. It's being used in people with advanced melanoma or lung cancer to see if it is safe and whether it can help shrink tumors.
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors +
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol No: MRNA-4359-P101
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05533697
Phase: I/II
Principal Investigators: Yuanbin Chen, MD
-
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer +
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Protocol No: NRG-LU008
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT05624996
Phase: III
Principal Investigators: Justin Rineer, MD
Objective
This study is comparing two types of radiation therapy, both given with chemotherapy, to see which helps patients with inoperable stage IIIIIC non-small cell lung cancer live longer and stay free from cancer progression.
-
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors +
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors
Protocol No: OBX115-23-01
Age Group: Adult
Disease Sites: Multiple Myeloma
NCT Id: NCT06060613
Phase: I/II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14052
File Name: OBX Subject Eligibility _Screening Checklist Version 19MAR2025 (1).docx
URL:
Objective
This study is testing a new kind of cell therapy called OBC-115 to see if it is safe and effective in people with advanced sold tumors.
-
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors +
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Protocol No: PRESERVE-003
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT05671510
Phase: III
Principal Investigators: Tirrell Johnson, MD
Objective
This study is measuring how long patients live after starting treatment, with results tracked over three years. Survival time is calculated from when a patient joins the study until death from any cause.
-
Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC) +
Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Protocol No: RYZ101-101
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT05595460
Phase: I
Principal Investigators: Justin Rineer, MD
Eligibility Document -
Attachment Id: 11754
File Name: Subject Eligibility _Screening Checklist for RYZ-101.docx
URL:
Objective
To study the safety and side effects of RYZ101 when given with standard chemotherapy in adults with advanced small cell lung cancer.
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More
ER Wait Times
Saturday, November 8, 2025 2:02 AM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 8 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 85 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 4 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 5 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 1 min |
| Orlando Health Emergency Room - Crossroads | Directions | 0 min |
| Orlando Health Emergency Room - Four Corners | Directions | 1 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 18 min |
| Orlando Health Emergency Room - Longwood | Directions | 2 min |
| Orlando Health Emergency Room - Osceola | Directions | 3 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 2 min |
| Orlando Health Emergency Room - Randal Park | Directions | 0 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 0 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 2 min |
| Orlando Health Horizon West Hospital | Directions | 3 min |
| Orlando Health Melbourne Hospital | Directions | 5 min |
| Orlando Health Orlando Regional Medical Center | Directions | 4 min |
| Orlando Health Sebastian River Hospital | Directions | 9 min |
| Orlando Health South Lake Hospital | Directions | 10 min |
| Orlando Health St. Cloud Hospital | Directions | 17 min |